Surmodics to Webcast Updated Fiscal 2016 Financial Guidance Conference Call on January 8

January 7, 2016 at 8:06 AM EST
PDF Version

Webcast is Live at 7:30 a.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 7, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast on Friday, January 8, at 7:30 a.m. CT (8:30 a.m. ET), to provide updated financial guidance for full fiscal year 2016. The Company will issue a news release earlier that morning.

Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will provide an overview of fiscal 2016 guidance, which includes the Creagh Medical acquisition, and will outline fiscal 2016 goals and long-term outlook and the status of integration. To access the webcast, go to the investor relations portion of the Company’s website at www.surmodics.com the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 10:30 a.m. CT on Friday, January 8, until 10:30 a.m. CT on Friday, January 15, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 2845259. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.

About Surmodics, Inc.

Surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. Our mission is to be a trusted partner to our customers by providing the most advanced surface modification technologies and in vitro diagnostic chemical components that help enhance the well-being of patients. The company’s core offerings include surface modification coating technologies that impart lubricity, prohealing and biocompatibility characteristics and components for in vitro diagnostic test kits and microarrays. Surmodics’ strategy is to build on the product and technical leadership within these fields, and expand the core offerings to generate opportunities for longer term sustained growth. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the Company makes with the SEC.

Source: Surmodics, Inc.

Surmodics, Inc.
Andy LaFrence, 952-500-7000
ir@surmodics.com